LEGN
Legend BiotechFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The primary-source bull case is that CARVYKTI is already commercial at scale: Q4 2025 net trade sales were about $1.9 billion for the year, more than 10,000 patients had been treated, the franchise reached profitability, and management still pointed to company-wide operating profit in 2026 if supply and site expansion keep converting into starts. [#PR-2026-03-10]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +18.4.
What can break
CARVYKTI safety remains material, including CRS, neurologic toxicities, HLH/MAS, prolonged cytopenias, enterocolitis, and secondary hematologic malignancies flagged in company materials.
Momentum
7
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $42.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $53.73
Why
Momentum7 · Δ7d -12.9
Value41 · Δ7d +0.0
Sentiment62 · Δ7d +18.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
7
26% active weight
Current posture
7d trendFlat
Δ7d
-12.9
Δ21d
-80.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
62
34% active weight
Current posture
7d trendImproving
Δ7d
+18.4
Δ21d
+25.6
Why this grade
Composite grade F. Momentum 7.0 / Value 41.1 / Sentiment 61.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$4.31B
Beta
0.11
Shares Out
185.74M
P/E (TTM) · Derived
-14.4
P/S (TTM)
4.13
P/FCF (TTM) · Derived
-17.06
Rev YoY
+56.7%
EPS YoY
-46.5%
Gross Margin
+51.5%
Op Margin
-21.6%
Net Debt
-$534.9M
Current Ratio
2.13
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology